Abstract
Glioblastoma multiforme (GBM) is the most common primary tumour of the central nervous system. The outcome after standard therapy, consisting of resection, radiation and chemotherapy, is poor: median survival is 40 to 60 weeks, with the tumour often recurring only a few millimetres away from the original location after gross total resection. The epidermal growth factor receptor (EGFR) is amplified and overexpressed in 40% to 50% of GBM, almost half of which co-expresses the mutated, constitutively activated EGFR variant III (EGFRvIII). As EGFR activation leads to cell proliferation, angiogenesis and reduced apoptosis, its increased activity may contribute to the aggressiveness of GBM. Therefore, to control these carcinogenic functions through EGFR inhibition is a logical therapeutic approach. Various trials of EGFR antagonists are ongoing, investigating tyrosine kinase inhibitors (TKIs), monoclonal antibodies (MAbs), RNA-based agents and vaccination against EGFRvIII. While TKIs, e.g. erlotinib and gefitinib, are currently the most advanced in clinical development, numerous trials indicate that a multiple target approach might be necessary to achieve therapeutically relevant effects.
Keywords: Combined therapy, epidermal growth factor receptor, EGFRvIII, erlotinib, glioblastoma multiforme, multitargeting, tyrosine kinase inhibitors, glioblastoma treatment, RNA-based agents, primary tumor
Current Signal Transduction Therapy
Title: Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment
Volume: 7 Issue: 1
Author(s): N. Merkur, M.-A. Westhoff, G. Karpel-Massler and M.-E. Halatsch
Affiliation:
Keywords: Combined therapy, epidermal growth factor receptor, EGFRvIII, erlotinib, glioblastoma multiforme, multitargeting, tyrosine kinase inhibitors, glioblastoma treatment, RNA-based agents, primary tumor
Abstract: Glioblastoma multiforme (GBM) is the most common primary tumour of the central nervous system. The outcome after standard therapy, consisting of resection, radiation and chemotherapy, is poor: median survival is 40 to 60 weeks, with the tumour often recurring only a few millimetres away from the original location after gross total resection. The epidermal growth factor receptor (EGFR) is amplified and overexpressed in 40% to 50% of GBM, almost half of which co-expresses the mutated, constitutively activated EGFR variant III (EGFRvIII). As EGFR activation leads to cell proliferation, angiogenesis and reduced apoptosis, its increased activity may contribute to the aggressiveness of GBM. Therefore, to control these carcinogenic functions through EGFR inhibition is a logical therapeutic approach. Various trials of EGFR antagonists are ongoing, investigating tyrosine kinase inhibitors (TKIs), monoclonal antibodies (MAbs), RNA-based agents and vaccination against EGFRvIII. While TKIs, e.g. erlotinib and gefitinib, are currently the most advanced in clinical development, numerous trials indicate that a multiple target approach might be necessary to achieve therapeutically relevant effects.
Export Options
About this article
Cite this article as:
Merkur N., Westhoff M.-A., Karpel-Massler G. and Halatsch M.-E., Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment, Current Signal Transduction Therapy 2012; 7 (1) . https://dx.doi.org/10.2174/157436212799278034
DOI https://dx.doi.org/10.2174/157436212799278034 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Anticancer α-Helical Peptides and Structure / Function Relationships Underpinning Their Interactions with Tumour Cell Membranes
Current Protein & Peptide Science Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future
Current Pharmaceutical Design Current Status and Perspectives in the Development of Camptothecins
Current Pharmaceutical Design Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry Replicative Oncolytic Herpes Simplex Viruses in Combination Cancer Therapies
Current Gene Therapy Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status
Current Pharmaceutical Design Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Novel Anticancer Strategy Aimed at Targeting Shelterin Complexes by the Induction of Structural Changes in Telomeric DNA: Hitting two Birds with one Stone
Current Cancer Drug Targets Exploration of the Medicinal Peptide Space
Protein & Peptide Letters RNA Interference in Cancer: Targeting the Anti-Apoptotic Protein c-FLIP for Drug Discovery
Mini-Reviews in Medicinal Chemistry Ex Vivo Gene Transfer for Improvement of Transplanted Pancreatic Islet Viability and Function
Current Pharmaceutical Design To Die or Not to Die: That is the Autophagic Question
Current Molecular Medicine Molecular Evidence of Compound Kushen Injection Against Lung Cancer: A Network Pharmacology-Based Investigation from Western Medicine to Traditional Medicine
Anti-Cancer Agents in Medicinal Chemistry Glutathione Transferases: Emerging Multidisciplinary Tools in Red and Green Biotechnology
Recent Patents on Biotechnology Hypoxia Inducible Factor-1 in Cancer Immune Suppression
Current Immunology Reviews (Discontinued) Recent Progress in Biomedical Applications of Magnetic Nanoparticles
Recent Patents on Nanotechnology ADAMTS9-AS2: A Functional Long Non-coding RNA in Tumorigenesis
Current Pharmaceutical Design